OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon. MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection. Of the 624 patients, an adequate number of lymph nodes (n > or = 12) had been harvested in 490 patients. These patients were stratified into LNR groups 1 (LNR < or = 0.4), 2 (0.4 < LNR < or = 0.7), and 3 (LNR > 0.7). Kaplan-Meier survival curve and log-rank test were used to evaluate the prognostic value of LNR. A Cox regression model was used for multivariate analyses. RESULTS: The 5-year DFS rate was 66.7% for patients with LNR1, 35.1% for those with LNR2, and 0% for patients with LNR3 (p < 0.0001). In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage. Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration. CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.
OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon. MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection. Of the 624 patients, an adequate number of lymph nodes (n > or = 12) had been harvested in 490 patients. These patients were stratified into LNR groups 1 (LNR < or = 0.4), 2 (0.4 < LNR < or = 0.7), and 3 (LNR > 0.7). Kaplan-Meier survival curve and log-rank test were used to evaluate the prognostic value of LNR. A Cox regression model was used for multivariate analyses. RESULTS: The 5-year DFS rate was 66.7% for patients with LNR1, 35.1% for those with LNR2, and 0% for patients with LNR3 (p < 0.0001). In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage. Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration. CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.
Authors: Leopoldo Sarli; Giovanni Bader; Domenico Iusco; Carlo Salvemini; Davide Di Mauro; Antonio Mazzeo; Gabriele Regina; Luigi Roncoroni Journal: Eur J Cancer Date: 2005-01 Impact factor: 9.162
Authors: Vincent Vinh-Hung; Claire Verschraegen; Donald I Promish; Gábor Cserni; Jan Van de Steene; Patricia Tai; Georges Vlastos; Mia Voordeckers; Guy Storme; Melanie Royce Journal: Breast Cancer Res Date: 2004-10-06 Impact factor: 6.466
Authors: Charles Sabbagh; François Mauvais; Cyril Cosse; Lionel Rebibo; Jean-Paul Joly; Didier Dromer; Christine Aubert; Sophie Carton; Bernard Dron; Innocenti Dadamessi; Bernard Maes; Guillaume Perrier; David Manaouil; Jean-François Fontaine; Michel Gozy; Xavier Panis; Pierre Henri Foncelle; Hugues de Fresnoy; Fabien Leroux; Pierre Vaneslander; Caroline Ghighi; Jean-Marc Regimbeau Journal: Int Surg Date: 2014 Jul-Aug